| Name | Title | Contact Details |
|---|
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Greater Houston Anesthesiology (GHA) is a Texas professional association dedicated to being the leading provider of perioperative and anesthesiology services in the Houston area. GHA began operations on January 1, 1996, following the merger of six
Eye Surgeon Associates is a Bettendorf, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Laerdal Medical Corporation maintains a national sales field team to assist customers with product information and demonstrations. Please use our contact form to request the name of your Laerdal Sales Representative.
Icario is a health action company that frees you to help people live healthier lives by helping you connect with them like they`re human. With over 100 million+ member connections, Icario is a health action platform that unites pioneering technology, data science, and behavioral insights to connect everyone to better health. Our mission is to make the world a healthier place, one person at a time. In 2020, Revel + NovuHealth joined forces to create Icario because we knew we could do better together—creating value by uniting pioneering technology, data science, and behavioral insights to make the world a healthier place, one person at a time. There is an island in the Aegean Sea where people live extremely long lives. They`re happy, too. Families are close. They eat well. They exercise. And they stay connected with each other, and not just by smartphone. This got us thinking. What if we apply what we learn from the Blue Zone island of Ikaria (our namesake), add pioneering technology and exabytes of data, and help healthcare connect better with everyone? We`ll have a lot more healthy, happy people, and that`s a pretty good thing. As an organization, we`re a collaborative team of pioneers, inventors, and systems thinkers. We speak truth, are driven by data, and sweat the details. We`re a friendly and easygoing group, but we work hard because we are mission-driven, we know a better way, and we`re here to make it happen.